Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

@inproceedings{Huang2014CombinationOP,
  title={Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms},
  author={Shih-Min A. Huang and Anlai Wang and Rita Greco and Zhifang Li and Fangxian Sun and Claude Barberis and Michel Tabart and Vinod D Patel and Laurent Schio and Raelene Hurley and Bo Chen and Hong Xuan Cheng and Christoph Lengauer and Jack Pollard and James C. Watters and Carlos Garc{\'i}a-Echeverr{\'i}a and Dmitri Wiederschain and Francisco J. Adri{\'a}n and Jingxin Zhang},
  booktitle={Oncotarget},
  year={2014}
}
Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a variety of mechanisms. Effective drug combination is one way to enhance therapeutic efficacy and combat resistance against JAK2 inhibitors. To identify potential combination partners for JAK2 compounds in MPN cell lines, we performed pooled shRNA screen targeting 5,000 genes in… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 4 Excerpts
Highly Influenced

US), inventorPim kinase inhibitors and methods of their use

MA CABurger, US, +7 authors CA Michelle Oakland
United States2010 • 2010
View 2 Excerpts
Highly Influenced

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.

Hematology. American Society of Hematology. Education Program • 2013
View 2 Excerpts

JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2013
View 2 Excerpts

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.

Proceedings of the National Academy of Sciences of the United States of America • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…